Nasdaq

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff Dexcom ONE, a wearable sensor and transmitter, puts people firmly in control of their ...
Business Wire

Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
Medscape

Dexcom’s 15-day CGM Adds Wear Time, Accuracy to Current G7

The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration, it is more ...
Business Wire

Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program. BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), ...